In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...
The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...
In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...
To leave our community click on the name at the top of your screen and ... is to collaborate with other scientists and ...
Zacks.com on MSN26d
AbbVie Secures FDA Approval for Parkinson's Disease Drug VyalevAbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV ... with advanced Parkinson's disease ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback